The number of COVID-19 vaccination doses administered in France rose to 154451978 as of Oct 27 2023. This dataset includes a chart with historical data for France Coronavirus Vaccination Total.

Since 2 April 2021, these files are no longer updated. Their communication will resume, but we are not in a position to give you a precise date to date. ### Vaccination against COVID-19 From the start of the vaccination campaign, the health authorities were provided with information to enable daily monitoring of the progress and deployment of the campaign on the territory. These, collected from institutions for the elderly and vaccination centres, were transmitted by the Regional Health Agencies. At the same time, Health Insurance has developed the Vaccine Covid Information System (VAC-SI), which is now fully operational after an analysis of the completeness and completeness of the data. The Vaccine Covid information system is powered by healthcare professionals carrying out vaccinations. Based on the use of these data, Santé Publique France publishes in open data the vaccine coverage indicators. #### What data? Data from the Vaccine Covid information system allows a near-real-time count (J-1) of the number of people who have been injected with Covid vaccine, taking into account the number of doses received, the vaccine, age, sex and geographical level (national, regional and departmental). The indicators available in open access on this dataset relate to the daily number of people with vaccinated comorbidities by date of injection (as well as this cumulative number), by age group They are declined on a scale: national, regional and departmental. Persons with co-morbidities are identified a priori by Cnam on the basis of the recommendations of the High Health Authority (HAS) for priority persons for COVID-19 Vaccination as identified as confirmed risk of serious form or death. Identification is carried out in particular for persons benefiting from long-term effects (ALD), or by targeting CIM codes. In particular, people with: diabetes, chronic kidney failure, COPD and respiratory failure, high blood pressure, heart failure, solid organ transplantation or allograft of haematopoietic stem cells, obesity, cancer and malignant haematologic diseases undergoing treatment with chemotherapy, some rare diseases (see list on the Ministry of Health website), trisomy 21. Only those for whom the department could be located are shown on the maps. Due to the time frame for entry into Covid Vaccine after vaccination in certain structures, a delay is needed to consolidate the data. **From 07/04/2021, the age of vaccinated persons will be calculated from the date of birth (and not the year of birth only). This implies, within Ehpad/USLS, a slight increase in immunisation coverage among professionals, which is accompanied by a slight decrease in immunisation coverage among residents. Overall, for all Vacsi indicators, this leads to some variations in age distributions. #### Precaution of data use Although the new injections are now seized over the water in Vaccin Covid, some injections since the end of December have not yet been entered in Vaccine Covid. In some regions, the Vaccine Covid data are now more complete than the increase made by the ARS, but in others this is not the case yet — especially in Île de France, Provence Alpes Côte d’Azur and Auvergne Rhône Alpes. The data that will now be published every day by Santé publique France at the date of injection will make it possible to report on this catch-up. In the departmental files, if a line for a number of vaccinated at a given date is missing, it is that there was no vaccination that day in the department. The age classes used are as follows: * 0: All ages * 24: 18-24 * 29: 25-29 * 39: 30-39 * 49: 40-49 * 59: 50-59 * 64: 60-64 The region (column “reg”) follows the codification of the INSEE Official Geographical Code, it is codified as follows: * 01: Guadeloupe * 02: Martinique * 03: Guyana * 04: The Meeting * 11: Ile-de-France * 24: Centre-Val de Loire * 27: Burgundy-Franche-Comté * 28: Normandy * 32: Haute-de-France * 44: Great East * 52: Country of the Loire * 53: Brittany * 75: New-Aquitaine * 76: Occitania * 84: Auvergne-Rhône-Alpes * 93: Provence-Alpes-Côte d’Azur * 94: Corsica

Update of 15/11/2022: update of the names of the vaccines The names of the vaccines have been standardized: the wording of the vaccine is followed by the name of the laboratory which produces it. Update of 23/09/2022: update of the Insee population and change made in the calculation of ages The update of the population and the calculation of ages was made on all the data, i.e. say on all the indicators updated since the end of December 2020. For the calculation of vaccination rates, the denominator is the population listed by INSEE on January 1, 2022 (and no longer on January 1, 2020) and the numerator corresponds to the all people who received an injection after excluding the deceased in 2021. The age for the numerator is also calculated as of January 1, 2022. From Friday April 8, 2022, the data update frequency is monthly. Update of 14/01/2022: addition of indicators relating to the recall Update of 02/07/2021: addition of the regional mesh General information: The data presents information relating to vaccination against Covid-19 by band age, type of vaccine, department and region of residence of patients. For each age group, type of vaccine, department and region, the following are presented: - the number of patients: having received at least a first injection; whose initial vaccination schedule has been completed; who received a booster injection (not calculated by type of vaccine); having received a booster shot and being eligible for the booster (not calculated by type of vaccine); - rates of patients: having received at least a first injection; whose initial vaccination schedule has been completed; having received a booster injection, reported to the Insee population (not calculated by type of vaccine); who received a booster injection, relative to the eligible population (not calculated by type of vaccine). Definitions of indicators: the first injection rate is the number of patients having received at least one first injection of vaccine, relative to the Insee population; the completed initial vaccination schedule rate is the number of patients, reported to the Insee population, whose vaccination was considered to have been completed before the implementation of the booster vaccination. The following cases are taken into account: two injections of vaccine (general case), a single injection of vaccine with a Covid-19 infection (before or after the first injection), a single injection with the Janssen vaccine or three injections of vaccine for immunocompromised patients; the booster rate is the number of patients who received a booster injection (i.e. patients with a completed initial vaccination schedule who received an additional injection of vaccine), relative to the Insee population (population comprising the most and under 18); the booster rate in the eligible population is the number of patients who received a booster injection (i.e. patients with a completed initial vaccination schedule who received an additional injection of vaccine), relative to the population eligible for the booster (patients over 18 years of age and whose initial vaccination schedule has been completed for at least 3 months, plus one month to allow patients time to organize themselves to receive their injection). These numbers and rates are proposed weekly and cumulatively since the start of the vaccination campaign. This same information is offered at the national level in the dataset. Source data used to compile the dataset: The available data (proportion of people vaccinated broken down by age group, type of vaccine administered and phase of the vaccination cycle) are calculated from information collected in the Covid Vaccine online service. Launched on January 4, 2021 by Health Insurance, this information system centralizes individual data on vaccination against Covid-19 to ensure traceability for the purposes of pharmacovigilance and management of the vaccination campaign. These individual data are pseudonymized and matched with the national health data system (SNDS) in order to provide vaccination rates according to the department of residence of the patients. An anonymous aggregate dataset is then created. Demography by department (source Insee) on 1 January 2022 is used as a reference population to calculate vaccination rates. Points of attention: It is possible that a patient receives only one injection and that his initial vaccination schedule is thus terminated: case of vaccines with one injection or patients who have already been affected by Covid-19, for example. It is possible that the two doses of vaccine injected into a patient are of two different types: a patient may thus have received a dose of the AstraZeneca vaccine as the first injection, then have received a dose of the Pfizer vaccine as the second injection. In order to translate this case into the data, the type of associated vaccine is that administered for the last injection; For the calculation of the rates: The denominator is the population listed by INSEE on 1 January 2022 The numerator is all the people who received an injection after excluding the deceased in 2021 The calculation of the age is on 1 January 2022 The breakdown by department of residence is not possible for patients not matched to the SNDS (approximately 1% of the population). These patients are attached to department 999 in the dataset. Territorial division: The department attached is that of the place of residence of the patients, and not that of the place of vaccination. The data is returned to metropolitan France and the DROMs. COM data are excluded due to insufficient numbers. Statistical secrecy: Out of respect for statistical secrecy (law of June 7, 1951) and so that the direct or indirect identification of individuals is impossible, no information on the numbers and rates of vaccination is communicated when the number of patients vaccinated is less than 11. The value of the indicator is then empty in the dataset and set to "Not significant" in the graphical representations. Numbers greater than 10 are rounded to ten. The rates are calculated from the actual numbers. Data update: The data available for download in the “Export” tab is updated monthly.

# IA2030 Action Plans and Impact Acceleration Reports: Survey responses from 931 national and sub-national staff (Immunization Agenda 2030 Full Learning Cycle 2022)

Note: This document includes markdown syntax to facilitate machine reading.

## Table of Contents
- Abstract
- Research Audience
- Credits
- Recommended Citation
- File List
- Related Data Sets
- Background
- Data Set Structure and Contents
- Data Cleaning, Data Privacy, and Anonymization
- Ethical Considerations
- Survey Implementation
- Survey Questionnaire Items
- Data Availability and Accessibility
- Copyright and License
- References

## Abstract

The Immunization Agenda 2030 (IA2030) has been endorsed at the World Health Assembly as the world’s strategy for immunization.

The Movement for IA2030 is a voluntary collective of immunization practitioners, principally from low- and middle-income countries, who have pledged to support each other to accelerate local action in support of this global immunization strategy.

This data set offers insights into how to understand national and sub-national challenges facing immunization programmes and what strategies show promise for addressing these challenges over time. It contains:
- raw, anonymized data in Excel CSV format. Copies of the three survey questionnaires are available for download in the Files section (below).
- responses to one, two, or three surveys from 931 national and subnational immunization practitioners participating in the Movement for Immunization Agenda (IA) 2030:

Survey 1: IA2030 Action Plan Survey: a 77-item questionnaire, fielded in May 2022, which asked respondents to identify a key challenge relevant to their immunization programme, root cause of the challenge, three corrective actions, and what they knew about vaccination coverage in their zone of intervention.

Survey 2: IA2030 Impact Acceleration Report Survey (2022): a 27-item questionnaire, fielded in June 2022, which asked respondents to report progress on implementation of their IA2030 Action Plan, including progress on vaccination coverage indicators.

Survey 3: IA2030 Impact Acceleration Report Survey (2023): a 60-item questionnaire, fielded in June 2023, which asked respondents to report progress on implementation of their IA2030 Action Plan, including progress on vaccination coverage indicators.

## Research Audience

Education and global health researchers with interest in human resources for health (HRH) and the characteristics, priority challenges, and experiences of national and sub-national immunization staff participating in the Movement for Immunization Agenda (IA) 2030.

## Credits

### Author

The Geneva Learning Foundation (TGLF)
18 Avenue Louis Casaï
CH1209 Geneva, Switzerland
research@learning.foundation

Principal Investigator and Corresponding Author
Reda Sadki, TGLF
reda@learning.foundation

Project Partners
- Biostat Global Consulting (BGC)
- Bridges to Development
- Centre for Change & Complexity in Learning (C3L)

Partner Roles and Responsibilities
- Design: TGLF
- Implementation (sample collection): TGLF
- Processing: TGLF, C3L
- Anonymization: BGC
- Submission: TGLF
- Maintenance of learning analytics database where data are stored: C3L

Funding
Wellcome Trust, Bill & Melinda Gates Foundation (BMGF)

## Recommended Citation

Action Plans and Impact Acceleration Reports: Responses from 931 national and sub-national staff (Immunization Agenda 2030 Full Learning Cycle). The Geneva Learning Foundation, 2023. (Version 1.0) [Data Set]. The Geneval Learning Foundation. https://doi.org/10.5281/zenodo.8298773

## File List

2023-09.IA2030_Action_Plans_and_Impact_Acceleration_Reports.README.md (this document)

2022-05.IA2030_Action_Plan_Survey.docx: List of items included in the Action Plan Survey

2022-06.IA2030_Impact_Acceleration_Report_Survey.docx: List of items included in the Impact Acceleration Report Survey questionnaire administered in June 2022.

2023-06.IA2030_Impact_Acceleration_Report_Survey.docx: List of additional items included in the Impact Acceleration Survey administered in June 2023 (the complete survey questionnaire also included all items included in the June 2022 Impact Acceleration Report Survey questionnaire).

2023-09.IA2030_Action_Plans_and_Impact_Acceleration_Reports_Survey_Dataset.csv: Anonymized Action Plans and Acceleration Reports Survey Dataset. Version 1: Geneva Learning Foundation (937 observations, 173 variables).

## Related Data Sets

The 2023-09.IA2030_Action_Plans_and_Impact Acceleration_Reports_Survey_Dataset.csv is a subset of data collected by The Geneva Learning Foundation (TGLF) during the first IA2030 Full Learning Cycle (FLC) during May 2022, June 2022, and June 2023. The complete IA 2030 Action Plans and Impact Acceleration Reports Survey data set is more comprehensive and includes information about respondent and programme characteristics as well as responses to open-text questions.

Researchers who would like to analyze the full set of unredacted responses are invited to contact the Geneva Learning Foundation to inquire about a data sharing agreement that would stipulate conditions of access (insights@learning.foundation).

The Geneva Learning Foundation, 2023. Value Creation Stories (VCS) weekly feedback survey, 2022 Full Learning Cycle (FLC) of the Movement for Immunization Agenda 2030 (IA2030) (Version 1.0). [Data Set]. The Geneva Learning Foundation. https://doi.org/10.5281/zenodo.7763922

The Geneva Learning Foundation, 2023. Full Learning Cycle (2022) Application for national and sub-national immunization staff to identify challenges and join the Movement for Immunization Agenda (IA 2030) (Version 1.0) [Data Set]. The Geneval Learning Foundation. https://doi.org/10.5281/zenodo.8199552

Additional data sets for the first Full Learning Cycle (FLC) of the Movement for Immunization Agenda 2030 (IA2030) are available from TGLF’s Insights Unit (insights@learning.foundation).

## Background

The Immunization Agenda 2030 (IA2030), the global immunization strategy for 2021-2030, set ambitious targets for global immunization coverage and other key indicators (World Health Organization [WHO], 2020).

In response to the WHO Director-General’s call for a social movement to ensure immunization remains a priority for global and regional health agendas and promote broad societal support for immunization (WHO, 2020), TGLF, working with its global community of over 35,000 alumni, developed a learning programme intended to contribute to a “Movement for Immunization Agenda 2030.” As part of their participation in the programme, IA2030 participants developed a locally tailored action plan designed to address a key challenge relevant to their immunization programme. A project kick-off phase, the “Impact Accelerator Launch Pad”, supported participants during their initial implementation stages, to create momentum for sustained action. One month after initiation of their Action Plan(s), participants were invited to complete an Impact Acceleration survey questionnaire to assess progress towards their goals. One year later, programme participants were invited to complete a second Impact Acceleration questionnaire to assess continued progress towards their goal.

This data set includes participants’ responses to one or more questionnaires documenting their IA2030 experience:
- Survey 1: IA2030 Action Plan Survey: a 77-item questionnaire, fielded in May 2022, which asked respondents to identify a key challenge relevant to their immunization programme, root cause of the challenge, three corrective actions, and what they knew about vaccination coverage in their zone of intervention.
- Survey 2: IA2030 Impact Acceleration Report Survey (2022): a 27-item questionnaire, fielded in June 2022, which asked respondents to report progress on implementation of their IA2030 Action Plan, including progress on vaccination coverage indicators.
- Survey 3: IA2030 Impact Acceleration Report Survey (2023): a 60-item questionnaire, fielded in June 2023, which asked respondents to report progress on implementation of their IA2030 Action Plan, including progress on vaccination coverage indicators.

## Data Set Structure and Contents

The data set has 937 observations and 173 variables. Contents include the following:
- 937 responses (532 English; 405 French) to the Action Plan Survey. Six individuals submitted two distinct Action Plans.
- 538 responses (278 English; 260 French) to the 2022 Impact Acceleration Report Survey
- 236 responses (126 English; 110 French) to the 2023 Impact Acceleration Report Survey
- Column A describes the type of data included in each row of the data file
- The first two rows of the data set hold the question text in English and in French
- Column B contains a unique identifier for each respondent. The ID is a simple string starting with a number to indicate a unique person and then a dash, and then a 1 or a 2 to indicate whether it is their first or second entry for the 2022 Impact Acceleration Report Survey.
- Columns D-F indicate the language each respondent used for each of the three questionnaires (EN = English; FR = French)
- The columns whose names start with I1 were collected as part of the Action Plan Survey, I2 as part of the 2022 Impact Acceleration Report Survey, and I3 as part of the 2023 Impact Acceleration Report Survey. The columns appear in left-to-right order in which the original surveys were administered.

## Data Cleaning, Data Privacy, and Anonymization

Duplicate surveys

# Title
Immunization Agenda 2030 (IA2030) 1st Movement Full Learning Cycle (FLC 2022) – “How are you doing?” Value Creation Stories Survey (Version 1.0)

# Research audience
Education researchers interested in the application of the “value creation stories” (VCS) conceptual framework elaborated by Etienne Wenger et al. in the study of communities of practice and other types of digital communities.

# Credits

## Author
The Geneva Learning Foundation
18 avenue Louis Casaï
CH-1209 Geneva, Switzerland
research@learning.foundation

### Principal Investigator and corresponding author
Reda Sadki, The Geneva Learning Foundation (TGLF)
reda@learning.foundation

## Project partners
Bridges to Development
University of South Australia Centre for Change and Complexity in Learning (C3L)

## Roles and responsibilities
- Design: The Geneva Learning Foundation
- Implementation (sample collection): The Geneva Learning Foundation
- Processing: The Geneva Learning Foundation, Bridges for Development, Centre for Complexity and Change in Learning (C3L)
- Anonymization: The Geneva Learning Foundation and Bridges for Development
- Data cleaning: Bridges to Development
- Submission: The Geneva Learning Foundation

## Funding sources or sponsorship that supported the data collection
Wellcome, Bill & Melinda Gates Foundation (BMGF)

## Recommended citation
The Geneva Learning Foundation, 2023. Value Creation Stories (VCS) weekly feedback survey, 2022 Full Learning Cycle (FLC) of the Movement for Immunization Agenda 2030 (IA2030) (Version 1.0). [Data Set]. The Geneva Learning Foundation. DOI: 10.5281/zenodo.7763922

# Description of the sample

## File list:

This file is IA2030_FLC_2022_Value_Creation_Stories.README.md

IA2030-EN_FLC_2022_Value_Creation_Stories-questions_mapping.csv : List of the survey’s questions and their code in English as well as their unit. (21 questions) - Version 1: Geneva Learning Foundation, 31 March 2023.

IA2030-EN_FLC_2022_Value_Creation_Stories.csv : Dataset Response of participants that replied in English. (n: 2101, obs:5601) - Version 1: Geneva Learning Foundation, 31 March 2023.

IA2030-FR_FLC_2022_Value_Creation_Stories-questions_mapping.csv: List of the survey’s questions and their code in English as well as their unit. (21 questions) - Version 1: Geneva Learning Foundation, 31 March 2023.

IA2030-FR_FLC_2022_Value_Creation_Stories-Google_translation.csv: Dataset Response of participants that replied in French translated to English using “Google Translate” (n: 1585, obs:4493) - Version 1: Geneva Learning Foundation, 31 March 2023.

IA2030-FR_FLC_2022_Value_Creation_Stories.csv: Dataset Response of participants that replied in French (n: 1585, obs:4493) - Version 1: Geneva Learning Foundation, 31 March 2023. Relationship between files: The questions codes data set are the same code as the column variables and can be connected.

## Relationship between files
The questions codes data set are the same code as the column variables and can be connected.

## Related data sets
This is a subset of data collected by The Geneva Learning Foundation (TGLF) during the 1st IA2030 Full Learning Cycle (FLC). The complete data set is more comprehensive, and includes: demographic information (gender, country), health system information (respondent’s health system level), respondents’ analyses of challenges and priorities.

Additional data sets for the first Full Learning Cycle (FLC) of the Movement for Immunization Agenda 2030 (IA2030) are available from The Geneva Learning Foundation (TGLF) Insights Unit [insights@learning.foundation](insights@learning.foundation)

## Other publicly accessible locations of the data
The Geneva Learning Foundation publishes data sets in relation to its Immunization Agenda 2030 (IA2030) Movement learning programme in the Zenodo open repository community: https://zenodo.org/communities/ia2030/

## 1. Purpose and Objectives

### Primary goal of the survey:
This survey had two goals in the context of TGLF’s IA2030 Movement Full Learning Cycle programme (2022):
1. Provide an asynchronous mechanism for support between peers (participants) and from the TGLF team; and
2. collect and measure programme participants’ value creation stories (VCS) during the programme.

Martin de Laat’s “value creation stories” (VCS) has been used primarily in small-scale, qualitative studies of communities of practice, online forums, and education activities.

This data set includes both quantitative (Likert) and qualitative (open text) responses to the VCS questions, collected over a period of four months (7 March – 20 June 2022) from a cohort that began with 6,185 participants on the start date.

## 2. Population and Sample

The target population were participants of the Geneva Learning Foundation’s Movement for Immunization Agenda 2030 (IA2030) learning programme. The initial cohort admitted to the programme was 6,185 individuals from 99 countries. Only participants who were formally admitted to the programme received the invitation to complete the survey.

Programme participants were free to choose if and when to report (self-selection), and their responses were not checked against any other measures (self-reporting).

### Languages: French and English

## 3. Survey Design and Methods

Data collection period: 7 March 2022 – 20 June 2022

Between 7 March and 20 June 2023, participants in the Geneva Learning Foundation’s “Immunization Agenda 2030” (IA2030) Movement Full Learning Cycle (FLC) were asked to respond to a questionnaire titled “How are you doing?”.

Participants received a personalized email with the request to share feedback about their experience during the week. The link to share feedback was also included in other reminder and information emails sent in response to participant needs.

The first survey was launched on the 11 of March 2022 and the last at 17 of March 2022, totalizing 15 requests. Participants could answer the survey at any time and as many times that they wished.

The group of 6,185 participants grew over the course of the Cycle, as additional participants were able to join the initiative throughout the four-month period.

### Software- or Instrument-specific information needed to interpret the data
- Automated translation of French data was performed using [Google Translate](https://translate.google.com/?sl=en&tl=fr&op=docs)
- Methods used for removing or anonymizing personal identifiers or sensitive information:
- Unique identifier: Unique identifiers were anonymized using MD5 Hashing via the web site [Miracle Salad](https://www.miraclesalad.com/webtools/md5.php.).Unique identifiers can be used to identify respondents who may have answered the survey more than once, at different points in time. This approach provides a method to anonymize sensitive data using MD5 hashing.*Limitation: MD5 hashing is a one-way function; it is not possible to dehash the data and recover the original information.**
- Macros developed in Excel to replace Country names in qualitative responses. (No country information were collected in this survey, but some respondents referred to their specific contexts in their responses.) The macro did not account for typos, in case any country information is found please contact: [research@learning.foundation](research@learning.foundation)

### Data collection start and end dates:
7 March 2023 until 20 June 2023

#### Events or circumstances during data collection that may have influenced results:
No requests for responses were sent during TGLF’s “Term break” between 16-30 April 2022.

## 4. Data Processing and Cleaning

- Incomplete or inconsistent responses: Not cleaned, as respondents were able to opt out of specific sections of survey or skip questions.
- Data transformations or imputations: None
- Treatment of outliers or extreme values: None

## 5. Variables and Measures

The survey included Likert scale questions and qualitative open texts based the conceptual framework for Value Creation Stories (VCS) developed by Wenger et. al. (2011). There are no derived or calculated variables. Items are Likert scale, multiple choice, and open text.

## 6. Data Quality and Reliability
All the responses done before or after the FLC period (7 March – 20 June 2022) were excluded of the sample.

## 7. Data Privacy and Anonymization

### Methods used for removing or anonymizing personal identifiers or sensitive information:
- Unique identifier: Unique identifiers were anonymized using MD5 Hashing via the web site https://www.miraclesalad.com/webtools/md5.php. Unique identifiers can be used to identify respondents who may have answered the survey more than once, at different points in time. This approach provides a method to anonymize sensitive data using MD5 hashing.
- Limitation: MD5 hashing is a one-way function; it is not possible to dehash the data and recover the original information.
- Macros developed in Excel to replace Country names in qualitative responses. (No country information were collected in this survey, but some respondents referred to their specific contexts in their responses.)

## 8. Data Availability and Accessibility
This data set is made available on Zenodo.org in the Zenodo community “Movement for Immunization Agenda 2030 (IA2030)”
https://zenodo.org/communities/ia2030/

Requests for additional information should be addressed to research@learning.foundation.

This is a subset of data collected by The